Integrated Clinical and Transcriptomic Profiling to Characterize Disease Phenotype
Demographics (2)
- COLLECTION_AGE - Age sample was collected (phv00493194.v1.p1)
- SEX - Biological sex (phv00493182.v1.p1)
Disease Events (1)
- AFFECTION_STATUS - Case control status of the subject for Essential Thrombocythemia, Polycythemia Vera, or Myelofibrosis (Primary or Secondary) (phv00493186.v1.p1)
Race and Ethnicity (2)
- Ethnicity - Self-reported ethnicity (phv00493188.v1.p1)
- RACE - Self-reported race (phv00493187.v1.p1)
Other (11)
- ANALYTE_TYPE - Analyte Type (phv00493191.v1.p1)
- BODY_SITE - Body site where sample was collected (phv00493190.v1.p1)
- CONSENT - Consent group as determined by DAC (phv00493181.v1.p1)
- HISTOLOGICAL_TYPE - Cell or tissue type or subtype of sample (phv00493192.v1.p1)
- IS_TUMOR - Cancer/Heme malignancy status (phv00493193.v1.p1)
- SAMPLE_ID - Sample ID Paired End 2 (phv00493189.v1.p1)
- SAMPLE_ID - Sample ID (phv00493184.v1.p1)
- SUBJECT_ID - Subject ID (phv00493185.v1.p1)
- SUBJECT_ID - Subject ID (phv00493180.v1.p1)
- SUBJECT_ID - Subject ID (phv00493183.v1.p1)
- TREATMENT_JAKi - Treatment by Ruxolitinib (phv00493195.v1.p1)